skip to Main Content

Publications 2010

The discovery of Isentress, the first in class HIV integrase inhibitor: from hit to drug

By Summa, Vincenzo
Edited By:Marcantoni, Enrico; Renzi, Gabriele
From Seminars in Organic Synthesis, “A. Corbella” Summer School, 35th, Gargnano, Italy, June 14-18, 2010 (2010), 247-268. Language: English, Database: CAPLUS

A review. A project done as part of an outstanding collaboration between scientists at IRBM in Rome and at Merck Research Labs. in West Point, Pennsylvania was described. Particularly, new class of compds. against HIV-Integrase was assessed. Due to its excellent potency, compd. 27 was further profiled in vitro and in vivo expts. When tested on an extensive panel of receptor and ion channel binding and enzyme inhibition assays it showed no significant activity. It was fully profiled in pharmacokinetic and safety studies on preclin. species, and advanced into clinic as MK-0518 to ultimately become Raltegravir or Isentress. Raltegravir met all preclin. criteria to be considered a very effective and safe HIV agent; the prediction of human PK provided the hypothesis that it would be a BID drug which was later confirmed in clin. studies. Isentress is currently used both in the first line and salvage therapies.

Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease

By Avolio, Salvatore; Summa, Vincenzo
From Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2010), 10(14), 1403-1422. Language: English, Database: CAPLUS, DOI:10.2174/156802610792232051

Hepatitis C virus (HCV) is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC). No vaccine is currently available to prevent hepatitis C, and the current std. of care (SOC) – pegylated interferon-α (PEG-IFN-α) in combination with ribavirin (RBV) – is only partially effective and it also presents side effects. Novel treatment options now under intensive development are focused on the discovery of inhibitors of HCV-specific enzymes. The HCV NS3 protease plays an essential role for viral replication and it is recognized as one of the most attractive targets for developing novel anti-HCV therapies. After two decades of research efforts a no. of potent active-site inhibitors of the NS3 protease have been generated and some of them are in late stage of clin. trials. A particularly interesting class of HCV NS3 protease inhibitors are based on depeptidized macrocyclic structures. The article reviews the recent progresses made in the discovery and development of macrocyclic inhibitors of the HCV NS3 protease as described in the most recent scientific literature (patent excluded), from a medicinal chem. perspective.

More info on PubMed.gov

Regioselective synthesis of 7,8-dihydropyrrolo[1,2-a]pyrimidin-4(6H)-ones and 7,8-dihydropyrrolo[1,2-a]pyrimidin-2(6H)-ones

By Donghi, Monica; Pesci, Silvia; Summa, Vincenzo; Koch, Uwe; Spieser, Stephane; Gardelli, Cristina
From Synlett (2010), (2), 235-239. Language: English, Database: CAPLUS, DOI:10.1055/s-0029-1218566

Regioselective synthesis of 7,8-dihydropyrrolo[1,2-a]pyrimidin-4(6H)-ones and 7,8-dihydropyrrolo[1,2-a]pyrimidin-2(6H)-onesAnnulated analogs e.g., I, II of 5,6-dihydroxypyrimidine-4-carboxylate ester and 5,6-dihydroxypyrimidine-4-carboxylamide were synthesized. The intermediary homoallylic amines were subjected to a ring-closure reaction under different reaction conditions. A notable pH-dependency of the ring closure leading to regioisomeric tetrahydropyrrolo[1,2-a]pyrimidines was obsd. Treatment with dimethyldioxirane and base led to 3-hydroxy-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidines while m-chloroperbenzoic acid or NBS afforded 3-hydroxy-2-oxo-2,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidines.

Read the article in full here

Kinase bypass approach for the treatment of Hepatitis C virus infection

By Narjes, Frank; Donghi, Monica; Meppen, Malte; Attenni, Barbara; Pacini, Barbara; Olsen, David B.; Carroll, Steve S.; MacCoss, Malcolm; Leone, Joseph F.; Di Marco, Annalise; et al
From Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 (2010), MEDI-347. Language: English, Database: CAPLUS

Infections caused by Hepatitis C Virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The NS5B RNA dependent RNA polymerase of HCV is responsible for the replication of viral RNA and has been a prime target in the search for novel HCV therapeutics. The application of a kinase bypass approach to the nucleoside inhibitor 2′-C-Methylcytidine will be presented. SAR around the 5′-phosphoramidate class of prodrugs 1 led to the identification of novel classes of compds., which formed efficiently nucleotide triphosphate 2 in HCV subgenomic replicon cells and in hepatocytes of different species. The in vivo profile of selected compds. in preclin. species will be presented.

Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways

By Marra, Emanuele; Uva, Paolo; Viti, Valentina; Simonelli, Valeria; Dogliotti, Eugenia; De Rinaldis, Emanuele; Lahm, Armin; La Monica, Nicola; Nicosia, Alfredo; Ciliberto, Gennaro; et al
From BMC Cancer (2010), 10, 129. Language: English, Database: CAPLUS, DOI:10.1186/1471-2407-10-129

Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI) anchored protein expressed not only in prostate but also in pancreas and bladder cancer as shown by immunohistochem. and mRNA anal. It has been targeted by monoclonal antibodies in preclin. animal models and more recently in a clin. trial in prostate cancer patients. The biol. role played in tumor growth is presently unknown. In this report we have characterized the contribution of PSCA expression to tumor growth. Methods: A bladder cell line was engineered to express a doxycycline (dox) regulated shRNA against PSCA. To shed light on the PSCA biol. role in tumor growth, microarray anal. was carried out as a function of PSCA expression. Expression of gene set of interest was further analyzed by qPCR. Results: Down regulation of the PSCA expression was assocd. with reduced cell proliferation in vitro and in vivo. Mice bearing s.c. tumors showed a reduced tumor growth upon treatment with dox, which effectively induced shRNA against PSCA as revealed by GFP expression. Pathway anal. of deregulated genes suggests a statistical significant assocn. between PSCA downregulation and activation of genes downstream of the IFN α/β receptor. Conclusions: These expts. established for the first time a correlation between the level of PSCA expression and tumor growth and suggest a role of PSCA in counteracting the natural immune response.

Read the article in full here

Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. [Erratum to document cited in CA151:356283]

By Dharmapuri, Sridhar; Peruzzi, Daniela; Mennuni, Carmela; Calaruso, Francesco; Giampaoli, Saverio; Barbato, Gaetano; Kandimalla, Ekambar R.; Agrawal, Sudhir; Scarselli, Elis; Mesiti, Giuseppe; et al
From Molecular Therapy (2010), 18(2), 447. Language: English, Database: CAPLUS, DOI:10.1038/mt.2009.276

The human telomerase reverse transcriptase (hTERT) is an attractive target for human cancer vaccination because its expression is reactivated in most human tumors. We have evaluated the ability of DNA electroporation (DNA-EP) and adenovirus serotype 6 (Ad6) to induce immune responses against hTERT in nonhuman primates (NHPs) (Macaca mulatta). Vaccination was effective in all treated animals, and the adaptive immune response remained detectable and long lasting without side effects. To further enhance the efficacy of the hTERT vaccine, we evaluated the combination of hTERT vaccine and a novel TLR9 agonist, referred to as immunomodulatory oligonucleotide (IMO). Monkeys were dosed weekly with IMO concurrently with the vaccine regimen and showed increases in cytokine secretion and activation of natural killer (NK) cells compared with the group that received vaccine alone. Using a peptide array, a specific profile of B-cell reactive epitopes was identified when hTERT vaccine was combined with IMO. The combination of IMO with hTERT genetic vaccine did not impact vaccine-induced TERT-specific cell-mediated immunity. Our results show that appropriate combination of a DNA-EP/Ad6-based cancer vaccine against hTERT with IMO induces multiple effects on innate and adaptive immune responses in NHPs.

More info on PubMed.gov

The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease.

By Monteagudo E; Fonsi M; Chu X; Bleasby K; Evers R; Pucci V; Orsale M V; Cianetti S; Ferrara M; Harper S; et al
From Xenobiotica; the fate of foreign compounds in biological systems (2010), 40(12), 826-39, Language: English, Database: MEDLINE

Compound A
((1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[12,11-b]quinoline-8-carboxamide) is a prototype of a series of subnanomolar inhibitors of genotypes 1, 2, and 3 hepatitis C virus (HCV) NS3/4A proteases. HCV NS3/4A protease inhibitors have demonstrated high antiviral effects in patients with chronic HCV infection and are likely to form a key component of future HCV therapy. Compound A showed excellent liver exposure in rats, which is essential for compounds intended to treat HCV. The compound was mainly eliminated intact in bile and showed greater than dose proportional systemic exposure in rats. Compound A demonstrated time- and temperature-dependent uptake into rat and human hepatocytes and proved to be a substrate for rat hepatic uptake transporter Oatp1b2 and for human hepatic uptake transporters OATP1B1 and OATP1B3. The liver selectivity observed for this compound is likely to be due to transporter-mediated hepatic uptake together with moderate passive permeability. Metabolism was mainly CYP3A-mediated and generated a reactive epoxide on the vinylcyclopropyl sulfonamide moiety that could be quenched by glutathione. Similar metabolic profiles of Compound A were obtained in liver microsomes of rats and humans. The oral bioavailability at 5 mg/kg was low due to extensive hepatic first-pass effect but clearly the intestinal absorption was enough to deliver a high amount of the compound to the liver. The metabolism and disposition properties of Compound A are particularly attractive to support its evaluation as a drug candidate for the treatment of hepatitis C.

More info on PubMed.gov

Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.

By Ferrara, Marco; Fiore, Fabrizio; Summa, Vincenzo; Gardelli, Cristina
From Bioorganic & Medicinal Chemistry Letters (2010), 20(17), 5031-5034. Language: English, Database: CAPLUS, DOI:10.1016/j.bmcl.2010.07.042

A series of 2-pyrrolidinyl-N-Me pyrimidones HIV integrase inhibitors has been explored leading to the identification of deriv. 13, which showed high activity at inhibiting viral replication in cell culture, favorable pharmacokinetic profile in two preclin. species, and an attractive profile against a panel of HIV-integrase mutants.

More info on PubMed.gov

A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.

By Peruzzi, Daniela; Gavazza, Alessandra; Mesiti, Giuseppe; Lubas, George; Scarselli, Elisa; Conforti, Antonella; Bendtsen, Claus; Ciliberto, Gennaro; La Monica, Nicola; Aurisicchio, Luigi
From Molecular Therapy (2010), 18(8), 1559-1567. Language: English, Database: CAPLUS, DOI:10.1038/mt.2010.104

Canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histol. appearance, tumor genetics, biol. behavior, and response to conventional therapies. As obsd. in humans, the telomerase reverse transcriptase (TERT) activity is largely confined to tumor tissues and absent in the majority of normal dog tissues. Therefore, dog TERT (dTERT) can constitute a valid target for translational cancer immunotherapy. We have evaluated the ability of adenovirus serotype 6 (Ad6) and DNA electroporation (DNA-EP) to induce immune responses against dTERT in dogs affected by malignant lymphoma (ML). The vaccine was combined with std. chemotherapy regimen [cyclophosphamide, vincristine, prednisone (COP)]. dTERT-specific immune response was induced in 13 out of 14 treated animals (93%) and remained detectable and long-lasting with the absence of autoimmunity or other side effects. Most interestingly, the survival time of vaccine/Chemo-treated dogs was significantly increased over historic controls of Chemo-treated animals (> 97.8 vs. 37 wk, resp., P = 0.001). Our results show that Ad6/DNA-EP-based cancer vaccine against dTERT overcomes host immune tolerance, should be combined with chemotherapy, induces long-lasting immune responses, and significantly prolongs the survival of ML canine patients. These data support further evaluation of this approach in human clin. trials.

More info on PubMed.gov

Immunological markers of cancer vaccine efficacy and their clinical relevance.

Cipriani B. (2009)
Biomark Med. 2009 Jun;3(3):253-64.

More info on PubMed.gov

Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.

By Malancona, Savina; Donghi, Monica; Ferrara, Marco; Martin Hernando, Jose I.; Pompei, Marco; Pesci, Silvia; Ontoria, Jesus M.; Koch, Uwe; Rowley, Michael; Summa, Vincenzo
From Bioorganic & Medicinal Chemistry (2010), 18(8), 2836-2848. Language: English, Database: CAPLUS, DOI:10.1016/j.bmc.2010.03.024

Chronic hepatitis C virus (HCV) infections are a significant medical problem worldwide. The NS5B Polymerase of HCV plays a central role in virus replication and is a prime target for the discovery of new treatment options. We recently disclosed 1H-benzo[de]isoquinoline-1,3(2H)-diones as allosteric inhibitors of NS5B Polymerase. Structural and SAR information guided us in the modification of the core structure leading to new templates with improved activity and toxicity/activity window.

More info on PubMed.gov

Enhancement of intestinal absorption of 2-methyl cytidine prodrugs.

By Cianetti, Simona; Cooper, Vincent Brett; Attenni, Barbara; Pucci, Vincenzo; Fiore, Fabrizio; Giuliano, Claudio; Laufer, Ralph; Gardelli, Cristina; Monteagudo, Edith; Narjes, Frank; et al
From Drug Delivery (2010), 17(4), 214-222. Language: English, Database: CAPLUS, DOI:10.3109/10717541003667814

The purpose of this study was to investigate the in vivo absorption enhancement of a nucleoside (phosphoramidate prodrug of 2′-methyl-cytidine) anti-viral agent of proven efficacy by means of intestinal permeation enhancers. Natural nucleosides are hydrophilic mols. that do not rapidly penetrate cell membranes by diffusion and their absorption relies on specialized transporters. Therefore, the oral absorption of nucleoside prodrugs and the target organ concn. of the biol. active nucleotide can be limited due to poor permeation across the intestinal epithelium. In the present study, the specificity, concn. dependence, and effect of four classes of absorption promoters, i.e. fatty acids, steroidal detergents, mucoadhesive polymers, and secretory transport inhibitors, were evaluated in a rat in vivo model. Sodium caprate and α-tocopheryl-polyethyleneglycol-1000-succinate (TPGS) showed a significant effect in increasing liver concn. of nucleotide (5-fold). These results suggested that both excipients might be suited in a controlled release matrix for the synchronous release of the drug and absorption promoter directly to the site of absorption and highlights that the effect is strictly dependent on the absorption promoter dose. The feasibility of such a formulation approach in humans was evaluated with the aim of developing a solid dosage form for the peroral delivery of nucleosides and showed that these excipients do provide a potential valuable tool in pre-clin. efficacy studies to drive discovery programs forward.

More info on PubMed.gov

Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1).

By Pescatore, Giovanna; Branca, Danila; Fiore, Fabrizio; Kinzel, Olaf; Bufi, Laura Llauger; Muraglia, Ester; Orvieto, Federica; Rowley, Michael; Toniatti, Carlo; Torrisi, Caterina; et al
From Bioorganic & Medicinal Chemistry Letters (2010), 20(3), 1094-1099. Language: English, Database: CAPLUS, DOI:10.1016/j.bmcl.2009.12.026

The discovery of a novel series of pyrrolo[1,2-a]pyrazin-1(2H)-one PARP inhibitors is described. Optimization led to compds. that display excellent PARP-1 enzyme potency and inhibit the proliferation of BRCA deficient cells in the low double-digit nanomolar range showing excellent selectivity over BRCA proficient cancer cells.

More info on PubMed.gov

Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells.

By Ferrigno, Federica; Branca, Danila; Kinzel, Olaf; Lillini, Samuele; Llauger Bufi, Laura; Monteagudo, Edith; Muraglia, Ester; Rowley, Michael; Schultz-Fademrecht, Carsten; Toniatti, Carlo; et al
From Bioorganic & Medicinal Chemistry Letters (2010), 20(3), 1100-1105. Language: English, Database: CAPLUS, DOI:10.1016/j.bmcl.2009.11.087

We describe an extensive SAR study in the 6-[4-fluoro-3-(substituted)benzyl]-4,5-dimethylpyridazin-3(2H)-one series which led to the identification of potent PARP-1 inhibitors, capable of inhibiting the proliferation of BRCA-1 deficient cancer cells in the low nanomolar range, and displaying >100-fold selectivity over the BRCA wild type counterparts. The series of compds. was devoid of hERG channel activity, and CYP inhibition and induction liabilities. Several analogs were stable in rat and human liver microsomes and displayed moderate rat clearance, with urinary excretion of parent as the major route of elimination.

More info on PubMed.gov

Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

By Torrisi, Caterina; Bisbocci, Monica; Ingenito, Raffaele; Ontoria, Jesus M.; Rowley, Michael; Schultz-Fademrecht, Carsten; Toniatti, Carlo; Jones, Philip
From Bioorganic & Medicinal Chemistry Letters (2010), 20(2), 448-452. Language: English, Database: CAPLUS, DOI:10.1016/j.bmcl.2009.12.002

A novel hexahydrobenzonaphthyridinone PARP-1 pharmacophore is reported. Subsequent SAR exploration around this scaffold led to selective PARP-1 inhibitors with low nanomolar enzyme potency, displaying good cellular activity and promising rat PK properties.

More info on PubMed.gov

Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.

By Scarpelli, Rita; Boueres, Julia K.; Cerretani, Mauro; Ferrigno, Federica; Ontoria, Jesus M.; Rowley, Michael; Schultz-Fademrecht, Carsten; Toniatti, Carlo; Jones, Philip
From Bioorganic & Medicinal Chemistry Letters (2010), 20(2), 488-492. Language: English, Database: CAPLUS, DOI:10.1016/j.bmcl.2009.11.127

Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitorsA potent series of substituted 2-phenyl-2H-indazole-7-carboxamides were synthesized and evaluated as inhibitors of poly (ADP-ribose) polymerase (PARP). This extensive SAR exploration culminated with the identification of substituted 5-fluoro-2-phenyl-2H-indazole-7-carboxamide analog I which displayed excellent PARP enzyme inhibition with IC50 = 4 nM, inhibited proliferation of cancer cell lines deficient in BRCA-1 with CC50 = 42 nM and showed encouraging pharmacokinetic properties in rats compared to the lead 6.

More info on PubMed.gov

Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs.

By Peruzzi, Daniela; Mesiti, Giuseppe; Ciliberto, Gennaro; La Monica, Nicola; Aurisicchio, Luigi
From Vaccine (2010), 28(5), 1201-1208. Language: English, Database: CAPLUS, DOI:10.1016/j.vaccine.2009.11.031

Pet dogs represent a valuable pre-clin. model to assess the efficacy of oncol. drugs. Addnl., canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histol. appearance, tumor genetics, biol. behavior and response to conventional therapies. The telomerase reverse transcriptase (TERT) is reactivated in most of human and dog tumors. Similarly, HER-2/neu oncoprotein is overexpressed in a proportion of canine breast cancers. Therefore, TERT and HER-2/neu can constitute valid tumor assocd. antigens (TAA), suitable targets for translational cancer immunotherapy in dogs. In this study, we have evaluated the ability of DNA electroporation (DNA-EP) and Adenovirus serotype 6 (Ad6) to induce immune responses against dog TERT (dTERT) and HER-2/neu in healthy dogs. Vaccination was effective in all treated animals and the adaptive immune response remained detectable and long-lasting in the absence of autoimmunity or other side-effects. Our results show that DNA-EP/Ad6-based cancer vaccine induces adaptive immune responses against TAA in canine subjects and support further evaluation of this approach in cancer dog patients.

More info on PubMed.gov

Novel P2-P4 macrocyclic inhibitors of HCV NS3/4A protease by P3 succinamide fragment depeptidization strategy.

By Pompei, Marco; Di Francesco, Maria Emilia; Pesci, Silvia; Koch, Uwe; Vignetti, Sue Ellen; Veneziano, Maria; Pace, Paola; Summa, Vincenzo
From Bioorganic & Medicinal Chemistry Letters (2010), 20(1), 168-174. Language: English, Database: CAPLUS, DOI:10.1016/j.bmcl.2009.11.005

Hepatitis C represents a serious worldwide health-care problem. Recently, we have disclosed a novel class of P2-P4 macrocyclic inhibitors of NS3/4A protease contg. a carbamate functionality as capping group at the P3 N-terminus. Herein we report our work aimed at further depeptidizing the P3 region by replacement of the urethane function with a succinamide motif. This peptidomimetic approach has led to the discovery of novel P2-P4 macrocyclic inhibitors of HCV NS3/4A protease with sub-nanomolar enzyme affinities. In addn. to being potent inhibitors of HCV subgenomic replication, optimized analogs within this series have also presented attractive PK properties and showed promising liver levels in rat following oral administration.

More info on PubMed.gov

Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-β particle formation in vitro

By Ingenito, Raffaele; Burton, Charlotte; Langella, Annunziata; Chen, Xun; Zytko, Karolina; Pessi, Antonello; Wang, Jun; Bianchi, Elisabetta
From Bioorganic & Medicinal Chemistry Letters (2010), 20(1), 236-239. Language: English, Database: CAPLUS, DOI:10.1016/j.bmcl.2009.10.128

Reverse cholesterol transport (RCT) is believed to be the primary mechanism by which HDL and its major protein apoA-I protect against atherosclerosis. Starting from the inactive 22-amino acid peptide representing the consensus sequence of the class A amphipathic helical repeats of apoA-I, we designed novel peptides able to mobilize cholesterol from macrophages in vitro, and to stimulate the formation of nascent HDL’ particles, with potency comparable to the entire apoA-I protein.

More info on PubMed.gov

Turbulent flow chromatography TFC-tandem mass spectrometry supporting in vitro/vivo studies of NCEs in high throughput fashion.

By Verdirame, Maria; Veneziano, Maria; Alfieri, Anna; Di Marco, Annalise; Monteagudo, Edith; Bonelli, Fabio
From Journal of Pharmaceutical and Biomedical Analysis (2010), 51(4), 834-841. Language: English, Database: CAPLUS, DOI:10.1016/j.jpba.2009.10.005

Turbulent Flow Chromatog. (TFC) is a powerful approach for online extn. in bioanal. studies. It improves sensitivity and reduces sample prepn. time, two factors that are of primary importance in drug discovery. In this paper the application of the ARIA system to the anal. support of in vivo pharmacokinetics (PK) and in vitro drug metab. studies is described, with an emphasis in high throughput optimization. For PK studies, a comparison between acetonitrile plasma protein pptn. (APPP) and TFC was carried out. The authors’ optimized TFC methodol. gave better S/N ratios and lower limit of quantification (LOQ) than conventional procedures. A robust and high throughput anal. method to support hepatocyte metabolic stability screening of new chem. entities was developed by hyphenation of TFC with mass spectrometry. An in-loop diln. injection procedure was implemented to overcome one of the main issues when using TFC, that is the early elution of hydrophilic compds. that renders low recoveries. A comparison between off-line solid phase extn. (SPE) and TFC was also carried out, and recovery, sensitivity (LOQ), matrix effect and robustness were evaluated. The use of two parallel columns in the configuration of the system provided a further increase of the throughput.

More info on PubMed.gov
Back To Top